Literature DB >> 1670882

Severe adverse interaction between pethidine and selegiline.

G L Zornberg, J A Bodkin, B M Cohen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1670882     DOI: 10.1016/0140-6736(91)92219-r

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  20 in total

1.  The selegiline transdermal system (emsam): a therapeutic option for the treatment of major depressive disorder.

Authors:  Lois Jessen; Lawrence J Kovalick; Albert J Azzaro
Journal:  P T       Date:  2008-04

Review 2.  Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects.

Authors:  J L Pilgrim; D Gerostamoulos; Olaf H Drummer
Journal:  Forensic Sci Med Pathol       Date:  2010-11-04       Impact factor: 2.007

Review 3.  [Anaesthesia in patients with Parkinson's disease].

Authors:  A Kalenka; J Hinkelbein
Journal:  Anaesthesist       Date:  2005-04       Impact factor: 1.041

Review 4.  Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.

Authors:  B K Young; R Camicioli; L Ganzini
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

Review 5.  Monoamine oxidase inhibitors. An update on drug interactions.

Authors:  M G Livingston; H M Livingston
Journal:  Drug Saf       Date:  1996-04       Impact factor: 5.606

6.  [Perioperative management of long-term medication].

Authors:  I Vogel Kahmann; W Ruppen; G Lurati Buse; D A Tsakiris; M Bruggisser
Journal:  Internist (Berl)       Date:  2011-01       Impact factor: 0.743

7.  Antiparkinsonian Agents : Clinically Significant Drug Interactions and Adverse Effects, and Their Management.

Authors:  A Dalvi; B Ford
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

Review 8.  Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease.

Authors:  P Chrisp; G J Mammen; E M Sorkin
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

Review 9.  Anaesthesia in elderly patients with neurodegenerative disorders: special considerations.

Authors:  Deborah A Burton; Grainne Nicholson; George M Hall
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 10.  Current place of monoamine oxidase inhibitors in the treatment of depression.

Authors:  Kenneth I Shulman; Nathan Herrmann; Scott E Walker
Journal:  CNS Drugs       Date:  2013-10       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.